BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-381@pharmaconomics
DTSTAMP:20260707T030413Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:TVTX Phase 2 — pegtibatinase (estimated date)
DESCRIPTION:Phase 2 trial results for pegtibatinase in Classical Homocystinuria (HCU) are due ~ Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/aex991_2025q4xearningsprex.htm\n\nTrack it: https://pharmaconomics.com/e/381
URL:https://pharmaconomics.com/e/381
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:TVTX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR